Rare diseases
Investigational molecules
Locations
Study on MK-2870, Pembrolizumab, and Chemotherapy for Patients with Advanced Gastroesophageal Cancer
FranceStudy of Pembrolizumab, Vibostolimab, and Chemotherapy for Patients with Newly Diagnosed Resectable Stage II-IIIB Non-Small Cell Lung Cancer
GreeceStudy Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels
CzechiaStudy Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer
BelgiumStudy of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery
AustriaStudy of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy
GermanyStudy on the Safety and Effectiveness of MK-2870 Alone or with Other Drugs for Patients with Colorectal, Pancreatic, and Biliary Tract Cancers
ItalyStudy of Sacituzumab Tirumotecan in Patients with Papillary Renal Cell Carcinoma and Variant Histology Urothelial Carcinoma (Rare Genitourinary Tumors)
SpainSacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy
AustriaStudy on the Safety and Effectiveness of MK-2870, Enfortumab Vedotin, and Pembrolizumab for Patients with Advanced Bladder Cancer
DenmarkStudy Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations
CzechiaStudy on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment
AustriaTell us about your condition – we search every trial in Europe and connect you with the right site.
